Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Big data reveals shifting patterns in rare cancer diagnosis

NCT ID NCT07317726

Knowledge-focused Sponsor: Suez Canal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at nearly 94,000 people with rare gastrointestinal carcinoid tumors to see if early detection has changed over time. Researchers analyzed cancer registry data from 2000 to 2022 to track whether tumors were found at earlier or later stages. The goal was to understand trends in diagnosis and survival, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

93,481 people

The number who actually took part.

Started

Dec 2000

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

the investigators analyzed the data from cancer registries participating in Surveillance, Epidemiology, and End Results (SEER) software for patients diagnosed with primary GI carcinoid tumors from 2000-2022 using a rate session to calculate the percent change and annual percent change in addition to incidence rates.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with gastrointestinal carcinoid tumors Exclusion Criteria: * patients with unknown age data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoid tumor Seer database analysis STAGE

More trials for these conditions

Other studies related to the condition(s) this trial covers.